Overview
LET'S BE BLUNT: Collaborating With Patients With Major Depressive Disorder to Achieve Full Functional Recovery
Expert Commentary
Click the"View Activity" button to view this activity.
View ActivityCME/CE is no longer available for this activity
In this, 60-minute activity, expert faculty review recommendations for the treatment of major depressive disorder (MDD), case vignettes, and “How I Do It” best practices. Discussions focus on the impact of measurement-based care for tracking symptoms of depression; assessment and management of treatment-related emotional blunting; as well as, strategies on how to involve patients in shared decision making. Join this activity and help your patients find the light again.
This activity is intended for healthcare professionals who treat major depressive disorder (MDD).
Major depressive disorder (MDD) is a common condition with a wide range of symptoms. Research has shown that medication alone or combination treatment with psychotherapy is effective in improving depression. Many patients with MDD feel hopeless, and medication discontinuation in these patients remains a barrier to successful outcomes. As depression is a common psychiatric disorder, it has significant clinical, quality-of-life, and economic consequences. Because patients are sometimes hesitant to report persistent symptoms of depression, other strategies for monitoring treatment-related changes are needed.
Upon completion of this activity, participants will be able to:
• Describe the burden of emotional blunting in patients with major depressive disorder (MDD)
• Review the latest research exploring how and to what extent different therapies may affect emotional blunting in patients with MDD
• Individualize treatment strategies for patients with MDD taking in to account the possible effects of emotional blunting in patient response to therapy
• Employ measurement-based care (MBC) and shared-decision making to assess emotional blunting as part of evaluation of patient response to treatment
• Describe the burden of emotional blunting in patients with major depressive disorder (MDD)
• Review the latest research exploring how and to what extent different therapies may affect emotional blunting in patients with MDD
• Individualize treatment strategies for patients with MDD taking in to account the possible effects of emotional blunting in patient response to therapy
• Employ measurement-based care (MBC) and shared-decision making to assess emotional blunting as part of evaluation of patient response to treatment
Sponsored by the Academy for Continued Healthcare Learning.
Supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.
Anita Clayton, MD
David C. Wilson Professor and Chair
Department of Psychiatry and Neurobehavioral Sciences
Professor of Clinical Obstetrics and Gynecology
University of Virginia School of Medicine
Charlottesville, VA
David C. Wilson Professor and Chair
Department of Psychiatry and Neurobehavioral Sciences
Professor of Clinical Obstetrics and Gynecology
University of Virginia School of Medicine
Charlottesville, VA
Roger McIntyre, MD, FRCPC
Professor of Psychiatry and Pharmacology
University of Toronto
Toronto, ON
Chairman and Executive Director, Brain and Cognition,
Depression and Bipolar Support Alliance (DBSA)
Chicago, IL
Clinical Professor, Department of Psychiatry and
Neurosciences
University of California School of Medicine
Riverside, CA
Michael Thase, MD
Professor of Psychiatry
Department of Psychiatry
Perelman School of Medicine at the University of Pennsylvania
Corporal Michael J. Crescenz
Veterans Affairs Medical Center
Philadelphia, PA
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been mitigated prior to this activity.
The following financial relationships have been provided:
Anita Clayton, MD, (Faculty)
Grant/Research Support recipient: Dare Bioscience, Janssen Pharmaceuticals, Relmada Therapeutics, and Sage Therapeutics Inc.
Roger McIntyre, MD, FRCPC, (Faculty)
Consultant (Occasional): AbbVie, Alkermes, Bausch Health, Eisai, Intra-Cellular, Janssen, Kris, Lundbeck
Neurocrine, NewBridge Pharmaceuticals, Novo Nordisk, Otsuka, Pfizer Inc., Purdue, Sanofi, Sunovion, Takeda
Grant/Research Support recipient: CIHR/GACD/Chinese National Natural Research Foundation
Speaker Bureau: AbbVie, Alkermes, Bausch Health, Eisai, Intra-Cellular, Janssen, Kris, Lundbeck, Neurocrine, NewBridge Pharmaceuticals, Novo Nordisk, Otsuka, Pfizer Inc., Purdue, Sanofi, Sunovion, Takeda
Chief Executive Officer: Braxia Scientific Corp.
Michael Thase, MD, (Faculty)
Consultant (Occasional): Acadia Pharmaceuticals Inc., Akili, Alkermes PLC, Allergan, Inc., Axsome Therapeutics, Inc., Biohaven, Inc., Bocemtium Consulting, Boehringer Ingelheim International, CatalYm GmbH, Clexio Biosciences, Gerson Lehrman Group, Inc., H. Lundbeck, A/S, Janssen Pharmaceuticals, Jazz Pharmaceuticals, Johnson & Johnson, Merck & Company, Inc., Otsuka Pharmaceutical Company, Ltd., Pfizer, Inc., Sage Pharmaceuticals, Seelos Pharmaceuticals, S.L., Luye Pharma Group, Ltd., Sunovion Pharmaceuticals, Inc., Takeda Pharmaceutical Company, Ltd.
Grant/Research Support Recipient: Acadia Pharmaceuticals Inc., Allergan, Inc., Axsome Therapeutics, Inc., Biohaven, Inc., Intracellular, Inc., Johnson & Johnson, Otsuka Pharmaceutical Company, Ltd., Sunovion Pharmaceuticals, Inc.
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: None
ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.
This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
This activity will take approximately 60 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity and complete the posttest and evaluation. To receive credit, 75% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.
The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.(NOTE: Nurse practitioners may participate in this educational activity and earn a certificate of completing as AANP accepts AMA PRA Category 1 Credits™ through its reciprocity agreements.)
